MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer

Abstract

Treatment with next-generation ALK inhibitors, particularly in the first-line setting, may lead to MET-driven resistance. Patients with acquired <i>MET</i> alterations may derive clinical benefit from therapies that target both ALK and MET.